Navigation Links
New therapeutic target for treatment of multiple sclerosis
Date:1/22/2008

Montreal, January 22, 2007 An international research team, led by a scientist from the Centre hospitalier de lUniversit de Montral (CHUM), has identified new therapeutic targets for the treatment of multiple sclerosis (MS). In the February issue of Nature Immunology, the team provides fresh answers concerning the role of novel adhesion molecules in the pathogenesis of MS, a chronic autoimmune disease of the nervous system that affects approximately 55,000 young adults in Canada.

Conducted by Dr. Alexandre Prat, a CHUM neurologist and researcher and a professor at the Universit de Montrals Faculty of Medicine, the study included collaborators from McGill University (Dr. S. David), the Universit de Montral (Dr. N. Arbour), the National Research Council of Canada (Dr. D. Stanimirovic) and University of Zrich (Dr. B. Becher). The team found that the adhesion molecule dubbed ALCAM (Activated Leukocyte Cell Adhesion Molecule), or CD166, plays a major role in the migration of certain types of leukocytes to the brain.

The researchers believe that the molecule, which is expressed by the endothelial cells of the brain, constitutes a novel target to restrict migration of immune cells to the brain, thereby dampening neuroinflammation and decreasing the lesions characteristic of MS. Understanding the molecular mechanisms of brain inflammation is essential in the development of new treatments for MS.

Dr. Prat and his team clearly demonstrate that CD166/ALCAM is involved in the inflammatory process by priming the migration of leukocytes across the blood-brain barrier (BBB). The investigation combined the results of an in vitro human BBB model and an in vivo experimental autoimmune encephalomyelitis mouse model. Normally, a limited number of immune cells are able to cross the BBB and penetrate the central nervous system. In MS and other neuroinflammatory diseases, the increased permeability of the BBB is associated with an increase in the transmigra
'/>"/>

Contact: Nathalie Forgue
nathalie.forgue.chum@ssss.gouv.qc.ca
51-489-080-001-4342
University of Montreal
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Ocera Therapeutics Receives Orphan Drug Status for AST-120 for Pouchitis
2. Transition Therapeutics Announces Appointment of Vice-President of Business Development
3. Cell Therapeutics, Inc. (CTI) Completes Acquisition of Lymphoma Drug Zevalin(R) From Biogen Idec for Sales and Marketing in the United States
4. Transition Therapeutics Announces Milestone Payment from Elan
5. ImaRx Therapeutics Submits Urokinase Data to FDA Supporting Extended Expiration Dating
6. Reckitt Benckiser Commences Cash Tender Offer for All Outstanding Shares of Adams Respiratory Therapeutics
7. Nektar Announces Agreement With Baxter to Develop New PEGylated Therapeutics for Hemophilia
8. Dr. Peter B. Corr Joins Team at Celtic Therapeutics as General Partner
9. PARIs eFlow Delivers Alnylam RNAi Therapeutic in Phase I Study
10. S*BIOs Oral JAK2 Inhibitor SB1518 Demonstrates Therapeutic Potential for the Treatment of Myeloproliferative and Other Hematological Disorders
11. New therapeutic options for newly diagnosed multiple myeloma patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2015)... February 28, 2015 In a recent ... of Game Change Athlete Development Services ... about the benefits of athlete development and player engagement ... the unique challenges that athletes face and how off-field ... success. , Fletcher became involved in athlete development issues ...
(Date:2/28/2015)... The Heart Fit Clinic started doing External Counterpulsation ... The Heart Fit Clinic is also selling the machines ... The goal is to scale the business to help ... buy External Counterpulsation machines can be difficult process. ... process and achieve the desired results. , The ...
(Date:2/28/2015)... February 28, 2015 Mew and Company, ... that they now provide business consulting services in addition ... corporate tax planning and succession planning. Company finances are ... experienced professionals. On top of this, complex Canadian tax ... corporate accounting. As a result, Mew and Company works ...
(Date:2/28/2015)... A study out of the University of Oxford ... the treatment of a hereditary ocular condition that leads ... Dr. Robert MacLaren, professor of ophthalmology at the University ... on January 16, 2014 , the study treated six ... mostly affects men and leads to the degeneration of ...
(Date:2/28/2015)... OR (PRWEB) February 28, 2015 Pioneer ... the 2015 Japan Architecture & Construction Materials Show, an ... join more than 1,000 suppliers and top manufacturers of ... Reclaimed wood products sourced and manufactured by ... have found popularity in Japan at restaurants, hotels, retailers, ...
Breaking Medicine News(10 mins):Health News:SCI TV Covers Athlete Development with Duncan Fletcher 2Health News:SCI TV Covers Athlete Development with Duncan Fletcher 3Health News:Clinicians Can Now Purchase External Counterpulsation with Heart Fit Clinic 2Health News:Vancouver Corporate Tax Accountants Now Provide Business Consulting Services 2Health News:New Gene Therapy Procedure Could Hold Key to Preventing Blindness for Certain Patients 2Health News:US Reclaimed Wood from Pioneer Millworks to be Featured at Architecture & Construction Materials Show in Tokyo. 2
... developed for preventing and treating the flue have shown ... dose to be effective.// The compounds, known collectively as ... relenza, or zanamivir, which the U.S. Food and Drug ... B. ,Researchers reported at the International Conference on ...
... to be worrisome threats, common pest control agent called ... treatments in eradicating deadly bacterial spores from buildings. Tests ... 50 years to control insect pests in buildings, grain ... than current treatments such as chlorine dioxide for killing ...
... giant GlaxoSmithKline (GSK), under fire regarding its smoking cessation drug, ... - in the wake of unproven reports in the UK, ... , ,Touted to be the world’s most successful smoking cessation ... June 2001. The cause for concern, however, was a safety ...
... University Hospital, a common cholesterol fighting drug, a statin ... heart complications by up to 20 percent for about ... heart events -- such as dying of heart disease ... Dr. Patrick Serruys,// professor of interventional cardiology at Erasmus ...
... the Marquette University School of Dentistry suggest chronic periodontal ... diabetes.//The research ties the incidence of diabetes in patients ... the bloodstream that triggers a reaction from the immune ... release proteins called cytokines that can disrupt production of ...
... University of Texas in US have found that African American ... women.// Ovarian cancer causes more deaths than any other cancer ... ethnicity is an independent risk factor in prognosis. US researchers ... 600 African American women with ovarian cancer. They find that ...
Cached Medicine News:Health News:Cholesterol Drug Helps After Angioplasty 2Health News:Cholesterol Drug Helps After Angioplasty 3
(Date:2/27/2015)... TORONTO , Feb. 27, 2015  Bionik Laboratories ... (the "Company"), announced today that it acquired Bionik Laboratories, ... Laboratories"), and completed the sale to qualified accredited investors ... for aggregate gross proceeds of approximately $6.2 million. Shares ... quoted on the OTC Markets under the symbol "DWTPD" ...
(Date:2/26/2015)... SAN DIEGO , Feb. 26, 2015  Tandem ... medical device company and manufacturer of the t:slim® and ... underwritten public offering of 5,250,000 shares of its common ... per share.  The net proceeds to Tandem from this ... underwriting discounts and commissions and other estimated offering expenses ...
(Date:2/26/2015)... WASHINGTON , Feb. 26, 2015  Mail-service ... consumers, employers and government health plans ... research released by the Pharmaceutical Care Management Association ... specialty drugs offers one of the easiest ways ... CEO Mark Merritt . "Policymakers should resist ...
Breaking Medicine Technology:Bionik Laboratories Raises $6.2 Million 2Bionik Laboratories Raises $6.2 Million 3Tandem Diabetes Care Announces Pricing of Underwritten Public Offering of Common Stock 2Tandem Diabetes Care Announces Pricing of Underwritten Public Offering of Common Stock 3PCMA: Report Shows High-Tech Specialty and Mail-Service Pharmacies Will Reduce Costs for Texas Employers, Consumers and Public Programs by $23.3 Billion 2
... , KRX-0401 + Capecitabine More Than Doubles Time ... Overall Survival vs. Capecitabine + Placebo in Patients with ... NEW YORK, June 1 Keryx Biopharmaceuticals, Inc. (Nasdaq: ... of KRX-0401 (perifosine), the Company,s Akt-inhibitor for cancer, in combination ...
... GATESHEAD, England, June 1 A leading GP has ... around the world the hope of combating the killer disease. , ... of Ateronon, the natural supplement,developed by Cambridge scientists, was a huge ... heart attacks and stroke. , Dozens of ...
Cached Medicine Technology:Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer 2Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer 3Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer 4Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer 5Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer 6Heart Disease Treatment Breakthrough 2Heart Disease Treatment Breakthrough 3
... physiological causes of minor knee pain like ... in concert with the motion of the ... and patellar tendon and assisting in the ... plastic support with high density foam padding ...
... Bariatric Knee Immobilizer is made of lightweight ... a breathable foam material that wicks moisture ... posterior aspect of the splint is uniquely ... The loop and lock closure straps allow ...
... breathable foam. Three piece design for precise ... loop closures. Lightweight rigid posterior stays with ... with optional hot and cold therapy Gel ... pain cycle by providing cold therapy to ...
... Neuroprene™ soft supports are a convenient, ... proprioceptive taping for common orthopedic conditions/instabilities. ... provide specific compression and lateral to ... (proprioceptors) in the skin and soft ...
Medicine Products: